[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HUE060653T2 - Gyógyászati kombinációk - Google Patents

Gyógyászati kombinációk

Info

Publication number
HUE060653T2
HUE060653T2 HUE17807555A HUE17807555A HUE060653T2 HU E060653 T2 HUE060653 T2 HU E060653T2 HU E17807555 A HUE17807555 A HU E17807555A HU E17807555 A HUE17807555 A HU E17807555A HU E060653 T2 HUE060653 T2 HU E060653T2
Authority
HU
Hungary
Prior art keywords
pharmaceutical combinations
pharmaceutical
combinations
Prior art date
Application number
HUE17807555A
Other languages
English (en)
Inventor
Giordano Caponigro
Zhu Alexander Cao
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60477982&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE060653(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of HUE060653T2 publication Critical patent/HUE060653T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/542Mucosal route oral/gastrointestinal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE17807555A 2016-06-03 2017-06-02 Gyógyászati kombinációk HUE060653T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662345389P 2016-06-03 2016-06-03

Publications (1)

Publication Number Publication Date
HUE060653T2 true HUE060653T2 (hu) 2023-04-28

Family

ID=60477982

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17807555A HUE060653T2 (hu) 2016-06-03 2017-06-02 Gyógyászati kombinációk

Country Status (26)

Country Link
US (3) US10485788B2 (hu)
EP (1) EP3463345B1 (hu)
JP (2) JP6805336B2 (hu)
KR (1) KR102439911B1 (hu)
CN (1) CN109890386B (hu)
AU (1) AU2017275650B2 (hu)
BR (1) BR112018074941A2 (hu)
CA (1) CA3026361A1 (hu)
CL (1) CL2018003421A1 (hu)
CO (1) CO2019000010A2 (hu)
CR (1) CR20190002A (hu)
DK (1) DK3463345T3 (hu)
FI (1) FI3463345T3 (hu)
HU (1) HUE060653T2 (hu)
IL (1) IL263431A (hu)
MA (1) MA45187A (hu)
MX (1) MX2018014973A (hu)
PH (1) PH12018502549A1 (hu)
PL (1) PL3463345T3 (hu)
PT (1) PT3463345T (hu)
RU (1) RU2759669C2 (hu)
SG (1) SG11201810793XA (hu)
SI (1) SI3463345T1 (hu)
UA (1) UA125436C2 (hu)
WO (1) WO2017210538A1 (hu)
ZA (1) ZA201900019B (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3463345T (pt) 2016-06-03 2023-01-06 Array Biopharma Inc Combinações farmacêuticas
MX2019003095A (es) * 2016-09-19 2019-07-04 Novartis Ag Combinaciones terapeuticas que comprenden un inhibidor de raf y un inhibidor de erk.
IL270224B1 (en) 2017-05-02 2024-04-01 Novartis Ag Combination therapy using trametinib and a defined RAF inhibitor
KR20220079652A (ko) * 2019-10-11 2022-06-13 에프. 호프만-라 로슈 아게 약물 투약 결정 디바이스 및 방법
EP4103286A4 (en) * 2020-02-10 2024-03-20 Cedars-Sinai Medical Center METHOD FOR TREATING PANCREATIC CANCER
JP7288220B2 (ja) 2021-03-29 2023-06-07 ダイキン工業株式会社 モータ、送風装置、および冷凍装置
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
WO2024126660A1 (en) * 2022-12-15 2024-06-20 F. Hoffmann-La Roche Ag Combination therapy for cancer treatment

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
DE60330227D1 (de) 2002-03-13 2010-01-07 Array Biopharma Inc N3-alkylierte benzimidazol-derivate als mek-hemmer
WO2008120004A1 (en) 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
ATE557015T1 (de) 2008-07-24 2012-05-15 Nerviano Medical Sciences Srl 3,4-diarylpyrazole als proteinkinaseinhibitoren
JP5527878B2 (ja) * 2009-07-30 2014-06-25 トムソン ライセンシング 表示装置及び音声出力装置
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
AU2012267888A1 (en) * 2011-06-07 2014-01-30 Caris Mpi, Inc. Molecular profiling for cancer
JP6150813B2 (ja) * 2011-11-11 2017-06-21 ノバルティス アーゲー 増殖性疾患の治療方法
BR112014011981B8 (pt) 2011-11-23 2022-07-19 Novartis Ag Formulações farmacêuticas sólidas orais, seus processos de preparação e usos
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
WO2014025688A1 (en) * 2012-08-07 2014-02-13 Novartis Ag Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
PT3702351T (pt) * 2012-10-19 2024-01-17 Array Biopharma Inc Formulação contendo um inibidor de mek
RU2015119218A (ru) * 2012-10-25 2016-12-20 Новартис Аг Комбинация
AU2014233805B2 (en) 2013-03-21 2018-10-18 Array Biopharma Inc. Combination therapy comprising a B-Raf inhibitor and a second inhibitor
CN105392763A (zh) 2013-07-18 2016-03-09 株式会社大赛璐 氧化物的制造方法
US20150087279A1 (en) * 2013-09-20 2015-03-26 Better Mousetrap, LLC Mobile accident processing system and method
CN106029074A (zh) * 2013-12-12 2016-10-12 诺华股份有限公司 用于治疗癌症的曲美替尼、帕尼单抗和达拉菲尼组合
CN105566225A (zh) * 2015-02-16 2016-05-11 苏州晶云药物科技有限公司 一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法
WO2016155670A1 (zh) * 2015-04-01 2016-10-06 苏州晶云药物科技有限公司 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
WO2017019279A1 (en) 2015-07-27 2017-02-02 Southern Research Institute Methods and compositions to treat cancers involving egfr
PT3463345T (pt) 2016-06-03 2023-01-06 Array Biopharma Inc Combinações farmacêuticas

Also Published As

Publication number Publication date
KR20190119507A (ko) 2019-10-22
BR112018074941A2 (pt) 2019-03-12
PH12018502549A1 (en) 2019-04-08
AU2017275650A1 (en) 2019-01-17
MA45187A (fr) 2019-04-10
ZA201900019B (en) 2023-04-26
US20190105303A1 (en) 2019-04-11
CA3026361A1 (en) 2017-12-07
US20200230108A1 (en) 2020-07-23
EP3463345A4 (en) 2020-02-26
JP6805336B2 (ja) 2020-12-23
CL2018003421A1 (es) 2019-07-19
CN109890386B (zh) 2022-05-24
JP2021054832A (ja) 2021-04-08
SI3463345T1 (sl) 2023-02-28
PL3463345T3 (pl) 2023-02-06
WO2017210538A1 (en) 2017-12-07
RU2018146812A3 (hu) 2020-10-09
DK3463345T3 (da) 2023-01-09
UA125436C2 (uk) 2022-03-09
US20230044943A1 (en) 2023-02-09
KR102439911B1 (ko) 2022-09-05
FI3463345T3 (fi) 2023-01-31
IL263431A (en) 2019-01-31
SG11201810793XA (en) 2018-12-28
JP2019525948A (ja) 2019-09-12
CO2019000010A2 (es) 2019-05-21
MX2018014973A (es) 2019-12-18
US10485788B2 (en) 2019-11-26
AU2017275650B2 (en) 2023-06-01
EP3463345B1 (en) 2022-11-02
RU2018146812A (ru) 2020-07-09
PT3463345T (pt) 2023-01-06
RU2759669C2 (ru) 2021-11-16
US11376239B2 (en) 2022-07-05
EP3463345A1 (en) 2019-04-10
CR20190002A (es) 2019-06-10
CN109890386A (zh) 2019-06-14

Similar Documents

Publication Publication Date Title
IL265360A (en) Pharmaceutical composition
IL266017A (en) Pharmaceutical compounds
GB201612092D0 (en) Pharmaceutical compounds
IL265260B (en) pharmaceutical preparations
GB201617758D0 (en) Pharmaceutical compounds
ZA201900540B (en) Pharmaceutical compounds
ZA201900019B (en) Pharmaceutical combinations
HUE052107T2 (hu) Gyógyszerészeti vegyületek
GB201617454D0 (en) Pharmaceutical compounds
EP3454899C0 (en) PHARMACEUTICAL COMPOSITION
GB201612095D0 (en) Pharmaceutical compounds
GB201703876D0 (en) Pharmaceutical combinations
IL254419A0 (en) New pharmaceutical uses
GB201615917D0 (en) Pharmaceutical composition
GB201617871D0 (en) Pharmaceutical compounds
GB201615914D0 (en) Pharmaceutical composition
GB201615910D0 (en) Pharmaceutical composition
GB201620519D0 (en) Pharmaceutical composition
GB201616088D0 (en) Pharmaceutical composition
HK1226067B (zh) 藥物化合物
GB201620517D0 (en) Pharmaceutical composition
GB201620513D0 (en) Pharmaceutical composition
GB201620516D0 (en) Pharmaceutical composition
GB201620515D0 (en) Pharmaceutical composition
GB201616767D0 (en) New pharmaceutical use